Table 4 Relation of molecular subgroups to clinicopathological parameters
Molecular subgroups | P value | |||
|---|---|---|---|---|
WNT (n = 4) | SHH (n = 12) | Non-WNT/SHH (n = 24) | ||
Age group (years) | ||||
< 3 (infants) | 0 (0%) | 2 (16.7%) | 6 (25%) | MC, p = 0.031* |
3-16 (pediatric age) | 3 (75%) | 6 (50%) | 18 (75%) | |
> 16 (adults) | 1 (25%) | 4 (33.3%) | 0 (0%) | |
Sex | ||||
Male | 1 (25%) | 5 (41.7%) | 16 (66.7%) | MC, p = 0.183 |
Female | 3 (75%) | 7 (58.3%) | 8 (33.3%) | |
Location of the mass | ||||
Midline | 4 (100%) | 1 (8.3%) | 22 (91.7%) | MC, p < 0.001* |
Lateral | 0 (0%) | 11 (91.7%) | 2 (8.3%) | |
Histopathological types | ||||
Classic medulloblastoma | 3 (75%) | 0 (0%) | 11 (45.8%) | MC, p < 0.001* |
Desmoplastic/nodular medulloblastoma | 0 (0%) | 10 (83.3%) | 0 (0%) | |
Large cell/anaplastic medulloblastoma | 1 (25%) | 2 (16.7%) | 13 (54.2%) | |
Degree of anaplasia | ||||
Slight anaplasia | 2 (50%) | 3 (25%) | 2 (8.3%) | MC, p = 0.255 |
Moderate anaplasia | 1 (25%) | 5 (41.7%) | 9 (37.5%) | |
Severe anaplasia | 1 (25%) | 4 (33.3%) | 13 (54.2%) | |
Risk stratification | ||||
Standard risk | 4 (100%) | 10 (83.3%) | 4 (16.7%) | MC, p < 0.001* |
High risk | 0 (0%) | 2 (16.7%) | 20 (83.3%) | |